Cytokine therapy for metastatic renal cell carcinoma

Masatoshi Eto, Seiji Naito

Research output: Contribution to journalReview articlepeer-review


Cytokine therapy for patients with metastatic renal cancer is based on observations suggesting this neoplasm may be responsive to immunotherapy. Two cytokines, interferon-alpha (IFN-alpha) and interleukin 2 (IL-2) induce tumor regression in 10% to 15% of patients with metastatic disease. Randomized trials demonstrate a modest survival advantage for patients treated with IFN-alpha, as compared with chemotherapy. The combination of IL-2 and IFN-alpha appears to be associated with improved response rates, but has no demonstrable effect on survival. The addition of other cytokines (e.g., GM-CSF) or chemotherapy to this combination has been investigated, but results do not suggest that they enhance the outcome. Patient selection remains an important issue in this patient population. Individuals who are asymptomatic and have limited pulmonary or soft-tissue disease are most likely to benefit. The addition of novel cytostatic agents to these regimens is now under way.

Original languageEnglish
Pages (from-to)1738-1744
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number10
Publication statusPublished - Oct 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytokine therapy for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this